Optibiotix hits the US

Optibiotix hits the US

Optibiotix, the York Science Park based business has agreed an extended partnership with Sacco, which has been manufacturing and supplying its cholesterol and blood pressure reducing strain LPLDL in Europe since March.

The story so far:

Now Sacco will do the same for Optibiotix’s patented product in the USA and the Rest of the World in return for 50 per cent of the profit.

As well as giving access to the world’s largest probiotic market in the US, the new agreement assists and extension of LPLDL into diary products utilising Sacco’s network in the dairy industry to develop commercial opportunities.

Stephen O’Hara comments: “This new agreement with Sacco significantly extends the scale of the commercial opportunity open to LPLDL to new application areas and territories, and reflects growing confidence from both companies in LPLDL’s market potential.”

Optibiotix Health announced yesterday it plans for a US launch of LPLDL, its cholesterol and blood pressure lowering product, at Supply Side West in Las Vegas, on September 27 and 28. OptiBiotix will co-exhibit with Sacco.

For the full story please see the York Press website.

"We chose Sacco as we have been impressed by their ability to introduce LPLDL to a global network of distributors and believe extending our partnership with them provides the best opportunity of quickly building revenues and developing LPLDL into a global brand. In addition, the ability to supply competitively priced ingredients from a single manufacturer across world markets simplifies the supply chain and contract negotiations with corporate partners." Stephen O’Hara - Chief Executive


Join the Success

If you want to be a part of the success stories, contact our team now!

Get in Touch

Get in Touch

If you'd like to find out more information on our facilities or book a tour of the park drop us a line and fill out your details here